The tumors in the shCCT2 group were significantly smaller and lighter in volume than those in the shNC group were, indicating that the knockdown of CCT2 in breast cancer cells delayed tumor growth in vivo (Fig. 6A–C). This evidence concerns the gene CCT2 and breast carcinoma.